NCT06446388View on ClinicalTrials.gov

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 1, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

QLS31905

Administered as an intravenous infusion.

DRUG

Oxaliplatin

130 mg/m2, intravenous infusion, D1, up to 8 cycles.

DRUG

Capecitabine

1000 mg/m2, oral, bid, D1-D14

DRUG

Gemcitabine

1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

DRUG

Cisplatin

25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.

DRUG

QL1706

5 mg/kg, intravenous infusion,D1

DRUG

Chemotherapy drug

Standard chemotherapy recommended by guidelines.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY